Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec
Video - CEO Clips: Cannara Biotech Graduates to Toronto Stock Exchange
Cannara Biotech Inc. (LOVE) Opens the Market
Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
Cannara Announces Grant of Options and RSUs
Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield
Cannara Biotech Enhances Financial Flexibility Through Strategic Asset Sale
Cannara Secures 5 Key Listings in Québec's New Vape Cartridge Category Including to be Released Live Rosin Vapes
Cannara Biotech to Host Investor Webcast on June 25th, 2025
Cannara Biotech Inc. (LOVFF) Q2 2025 Earnings Call Transcript
Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike
Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
Cannara Biotech Reports Q3 2024 Financial Results
Cannara Biotech Reports Q2 2024 Financial Results
Cannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion
Cannara Biotech Announces Engagement of Market Maker Services from Independent Trading Group ("ITG")
The 7 Most Undervalued Cannabis Stocks to Buy in December
Cannara Biotech Announces Notice Of Annual General Meeting Of Shareholders To Be Held Virtually On January 25th, 2024
Cannara Biotech to Host Investor Webcast on Thursday December 14th, 2023
Cannara Biotech Reports Fourth Quarter and 2023 Fiscal Year Results: Record Growth and Profitability Continues
7 Smoking-Hot 420 Stocks to Buy in 2023
Cannara Biotech Inc. Reports Record Q3 2023 Financial Results with Net Revenues of $15.9 Million and Net Income of $2.9 million
Cannara Biotech Inc. to Host Investor Webcast on August 17th, 2022
Cannara Biotech Shares Surge On 983% QoQ Revenue Growth, Positive Adjusted EBITDA
Cannara Biotech Cannabis Co. Slightly Beats Estimates, Posts $7.2M In Q3 2021 Revenue
Cannabis Industry Investor Presentations Now Available for On-Demand Viewing
Cannara Biotech Cannabis Co. Expects To Post $7.1M In Q3 Revenue After Successful Market Launch In Quebec
Cannara Biotech to Webcast Live at VirtualInvestorConferences.com June 30th at 11:30 ET
Cannabis Co. Green Organic Dutchman Completes Sale Of Quebec Facility To Cannara Biotech
/C O R R E C T I O N -- Cannara Biotech Inc./
Cannara Biotech Enters Into Agreement to Acquire TGOD's State-of-the-art Cultivation and Manufacturing Facility in Valleyfield, Quebec
Cannara Biotech Receives Sales Licence from Health Canada
Cannara Biotech Inc. (CSE: LOVE) announces Year-End and Q4 2020 Results